Publication Highlights the Impact of the Aetna/CVS Merger on the Biosimilars Market

Blue Ash, OH - - MarketVision’s Dr. Joel Schindler shares his perspective surrounding the merger in a recent publication by Biosimilar Development.

Mergers and acquisitions are commonplace in healthcare as well as other categories, but this merger is different.

“The desired merger of CVS and Aetna, however, introduces a dramatically different dynamic — the vertical integration of two different types of businesses, a pharmacy/drug distribution entity and an insurance company, to create a new type of healthcare system.”

For a printable version, click Here

Original publication

https://www.biosimilardevelopment.com/doc/how-will-the-cvs-aetna-merger-impact-biosimilars-0001